NASDAQ:INDP Indaptus Therapeutics (INDP) Stock Forecast, Price & News $2.78 +0.29 (+11.65%) (As of 09/26/2023 ET) Add Compare Share Share Today's Range$2.52▼$2.8550-Day Range$1.75▼$3.9552-Week Range$1.25▼$4.08Volume24,648 shsAverage Volume25,028 shsMarket Capitalization$23.35 millionP/E RatioN/ADividend YieldN/APrice Target$12.00 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media Indaptus Therapeutics MarketRank™ ForecastAnalyst RatingBuy3.00 Rating ScoreUpside/Downside331.7% Upside$12.00 Price TargetShort InterestHealthy0.39% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.65Based on 4 Articles This WeekInsider TradingAcquiring Shares$142,052 Bought Last QuarterProj. Earnings GrowthGrowingFrom ($1.92) to ($1.88) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.66 out of 5 starsMedical Sector118th out of 963 stocksPharmaceutical Preparations Industry36th out of 450 stocks 3.5 Analyst's Opinion Consensus RatingIndaptus Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $12.00, Indaptus Therapeutics has a forecasted upside of 331.7% from its current price of $2.78.Amount of Analyst CoverageIndaptus Therapeutics has only been the subject of 1 research reports in the past 90 days. Previous Next 5.0 Short Interest Percentage of Shares Shorted0.39% of the float of Indaptus Therapeutics has been sold short.Short Interest Ratio / Days to CoverIndaptus Therapeutics has a short interest ratio ("days to cover") of 1.3, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Indaptus Therapeutics has recently decreased by 51.61%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldIndaptus Therapeutics does not currently pay a dividend.Dividend GrowthIndaptus Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for INDP. Previous Next 2.6 News and Social Media Coverage News SentimentIndaptus Therapeutics has a news sentiment score of 0.65. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.84 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for Indaptus Therapeutics this week, compared to 0 articles on an average week.MarketBeat Follows4 people have added Indaptus Therapeutics to their MarketBeat watchlist in the last 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Indaptus Therapeutics insiders have bought more of their company's stock than they have sold. Specifically, they have bought $142,052.00 in company stock and sold $0.00 in company stock.Percentage Held by Insiders27.10% of the stock of Indaptus Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 21.24% of the stock of Indaptus Therapeutics is held by institutions. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for Indaptus Therapeutics are expected to grow in the coming year, from ($1.92) to ($1.88) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Indaptus Therapeutics is -1.58, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Indaptus Therapeutics is -1.58, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioIndaptus Therapeutics has a P/B Ratio of 0.93. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Indaptus Therapeutics (NASDAQ:INDP) StockIndaptus Therapeutics, Inc., a clinical biotechnology company, develops various anti-cancer and anti-viral immunotherapy products. Its lead clinical candidate is Decoy20 used to produce single agent activity and/or combination therapy-based durable responses of lymphoma, hepatocellular, colorectal, and pancreatic tumors, as well as chronic hepatitis B virus and human immunodeficiency virus infection, which is in Phase 2 clinical trial. The company was formerly known as Intec Parent, Inc. and changed its name to Indaptus Therapeutics, Inc. in August 2021. Indaptus Therapeutics, Inc. is headquartered in New York, New York.Read More INDP Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart INDP Stock News HeadlinesSeptember 26, 2023 | finance.yahoo.comRegistration Is Now Open For Tribe Public’s Webinar Event "Immunotherapy Reimagined" Featuring Indaptus Therapeutics’ CEO On Friday, September 29, 2023September 22, 2023 | americanbankingnews.comHC Wainwright Reiterates Buy Rating for Indaptus Therapeutics (NASDAQ:INDP)September 27, 2023 | Edge On The Street (Ad)Is Gold Really Boring?Many investors perceive gold as a "boring" investment. But according to MoneyWeek, that's a good thing. Gold helps investors sleep soundly as it preserves wealth and creates a hedge against inflation. Today, there's a unique way to invest in gold, with real advantages over coins and mining stocks. September 20, 2023 | americanbankingnews.comIndaptus Therapeutics (NASDAQ:INDP) Trading Up 7.3%September 19, 2023 | finance.yahoo.comIndaptus Therapeutics Doses First Patient in Second Cohort of Single Dose Ranging Study of Decoy20September 6, 2023 | finance.yahoo.comIndaptus Therapeutics to Present at the H.C. Wainwright 25th Annual Global Investment ConferenceAugust 29, 2023 | finance.yahoo.comFavourable Signals For Indaptus Therapeutics: Numerous Insiders Acquired StockAugust 14, 2023 | finance.yahoo.comIndaptus Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate UpdateSeptember 27, 2023 | Edge On The Street (Ad)Is Gold Really Boring?Many investors perceive gold as a "boring" investment. But according to MoneyWeek, that's a good thing. Gold helps investors sleep soundly as it preserves wealth and creates a hedge against inflation. Today, there's a unique way to invest in gold, with real advantages over coins and mining stocks. August 11, 2023 | markets.businessinsider.comMaxim Group Remains a Buy on Indaptus Therapeutics (INDP)August 10, 2023 | finance.yahoo.comIndaptus Therapeutics Announces Opening of Next Cohort in Single Dose Ranging Study of Decoy20August 7, 2023 | finance.yahoo.comIndaptus Therapeutics Appoints Industry Veteran Roger Waltzman, M.D. Chief Medical OfficerMay 31, 2023 | finance.yahoo.comIndaptus Therapeutics to Present at the Jefferies Healthcare Conference 2023May 31, 2023 | finance.yahoo.comIndaptus Therapeutics to Present at the Jefferies Healthcare Conference 2023May 9, 2023 | finance.yahoo.comFollowing Granting of Indian Patent, Indaptus Therapeutics Achieves Patent Protection in 32 Countries for Decoy Immunotherapy PlatformMay 4, 2023 | markets.businessinsider.comWhat 4 Analyst Ratings Have To Say About Indaptus TherapeuticsMay 4, 2023 | msn.comHC Wainwright & Co. Reiterates Indaptus Therapeutics (INDP) Buy RecommendationMay 2, 2023 | finance.yahoo.comWe Think Indaptus Therapeutics (NASDAQ:INDP) Needs To Drive Business Growth CarefullyMay 1, 2023 | benzinga.comIndaptus Therapeutics' Chief Scientific Officer Michael Newman, Ph.D. Named a Chair of the 4th STING & TLR-Targeting Therapies SummitMay 1, 2023 | finance.yahoo.comIndaptus Therapeutics’ Chief Scientific Officer Michael Newman, Ph.D. Named a Chair of the 4th STING & TLR-Targeting Therapies SummitApril 20, 2023 | finance.yahoo.comIndaptus Therapeutics to Present at the Planet MicroCap Showcase: VEGAS 2023April 19, 2023 | msn.comIndaptus Therapeutics Says Antitumor Platform Demonstrates Preclinical Efficacy Across Cancer IndicationsApril 19, 2023 | finance.yahoo.comIndaptus Therapeutics Presents Data Demonstrating Preclinical Efficacy of Decoy, its Bacteria-Based Immunotherapy Platform Technology, at the American Association for Cancer Research Conference 2023April 19, 2023 | finance.yahoo.comUPDATE -- Indaptus Therapeutics Presents Data Demonstrating Preclinical Efficacy of Decoy, its Bacteria-Based Immunotherapy Platform Technology, at the American Association for Cancer Research Conference 2023April 17, 2023 | finance.yahoo.comIndaptus Therapeutics Receives Brazilian Patent Allowance for Decoy PlatformMarch 22, 2023 | finance.yahoo.comQuite a few insiders invested in Indaptus Therapeutics, Inc. (NASDAQ:INDP) last year which is positive news for shareholdersMarch 22, 2023 | finance.yahoo.comIndaptus Therapeutics to Present at the Investor Summit ConferenceSee More Headlines Receive INDP Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Indaptus Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address INDP Company Calendar Last Earnings8/14/2023Today9/27/2023Next Earnings (Estimated)11/09/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:INDP CUSIPN/A CIK1857044 Webintecpharma.com Phone(646) 427-2727Fax972-2586-9176Employees6Year FoundedN/APrice Target and Rating Average Stock Price Forecast$12.00 High Stock Price Forecast$12.00 Low Stock Price Forecast$12.00 Forecasted Upside/Downside+331.7%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)($1.76) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-14,320,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-63.56% Return on Assets-57.05% Debt Debt-to-Equity RatioN/A Current Ratio9.45 Quick Ratio9.45 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$2.98 per share Price / Book0.93Miscellaneous Outstanding Shares8,400,000Free Float6,124,000Market Cap$23.35 million OptionableNot Optionable Beta1.04 Ten Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free Report Key ExecutivesMr. Jeffrey A. Meckler (Age 56)CEO & Director Comp: $888.32kMr. Walt Addison Linscott Esq. (Age 62)Chief Operating Officer Comp: $666.63kDr. Michael J. Newman Ph.D. (Age 67)Founder, Chief Scientific Officer & Director Mr. Nir Sassi (Age 47)CFO, Sec. & Treasurer Dr. Roger J. Waltzman M.B.A. (Age 55)M.D., Chief Medical Officer Key CompetitorsSensei BiotherapeuticsNASDAQ:SNSEGenprexNASDAQ:GNPXVallon PharmaceuticalsNASDAQ:VLONSeelos TherapeuticsNASDAQ:SEELKinetaNASDAQ:KAView All CompetitorsInsiders & InstitutionsStrategy Asset Managers LLCSold 10,000 shares on 8/25/2023Ownership: 0.540%Glen R AndersonBought 23,934 shares on 8/14/2023Total: $56,005.56 ($2.34/share)Glen R AndersonBought 44,354 shares on 8/10/2023Total: $86,046.76 ($1.94/share)Investment House LLCBought 12,653 shares on 8/8/2023Ownership: 1.289%Boyan Vesselinov LitchevBought 500 shares on 12/1/2022Total: $935.00 ($1.87/share)View All Insider TransactionsView All Institutional Transactions INDP Stock - Frequently Asked Questions Should I buy or sell Indaptus Therapeutics stock right now? 1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Indaptus Therapeutics in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" INDP shares. View INDP analyst ratings or view top-rated stocks. What is Indaptus Therapeutics' stock price forecast for 2023? 1 equities research analysts have issued 12-month price objectives for Indaptus Therapeutics' stock. Their INDP share price forecasts range from $12.00 to $12.00. On average, they anticipate the company's stock price to reach $12.00 in the next year. This suggests a possible upside of 331.7% from the stock's current price. View analysts price targets for INDP or view top-rated stocks among Wall Street analysts. How have INDP shares performed in 2023? Indaptus Therapeutics' stock was trading at $1.45 on January 1st, 2023. Since then, INDP shares have increased by 91.7% and is now trading at $2.78. View the best growth stocks for 2023 here. When is Indaptus Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, November 9th 2023. View our INDP earnings forecast. How were Indaptus Therapeutics' earnings last quarter? Indaptus Therapeutics, Inc. (NASDAQ:INDP) released its quarterly earnings data on Monday, August, 14th. The company reported ($0.39) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.58) by $0.19. What is Indaptus Therapeutics' stock symbol? Indaptus Therapeutics trades on the NASDAQ under the ticker symbol "INDP." Who are Indaptus Therapeutics' major shareholders? Indaptus Therapeutics' stock is owned by many different institutional and retail investors. Top institutional investors include Investment House LLC (1.29%) and Strategy Asset Managers LLC (0.54%). Insiders that own company stock include Boyan Vesselinov Litchev, Glen R Anderson, Jeffrey A Meckler, Michael James Newman and Walt Addison Linscott. View institutional ownership trends. How do I buy shares of Indaptus Therapeutics? Shares of INDP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Indaptus Therapeutics' stock price today? One share of INDP stock can currently be purchased for approximately $2.78. How much money does Indaptus Therapeutics make? Indaptus Therapeutics (NASDAQ:INDP) has a market capitalization of $23.35 million. The company earns $-14,320,000.00 in net income (profit) each year or ($1.76) on an earnings per share basis. How can I contact Indaptus Therapeutics? Indaptus Therapeutics' mailing address is 12 Hartom Street, Har Hotzvim, Jerusalem 777512. The official website for the company is intecpharma.com. The company can be reached via phone at (646) 427-2727, via email at will.oconnor@sternir.com, or via fax at 972-2586-9176. This page (NASDAQ:INDP) was last updated on 9/27/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Indaptus Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.